SEC filings and other documents

Lead in vivo CAR-T asset targets broad autoimmune and oncology markets with scalable, modular delivery.

Q1 2026 saw strong clinical progress, major asset acquisition, and a widened net loss on higher expenses.

TPST-2003 dual CAR-T achieves deep, durable responses and strong safety in rrMM, including EMD.

Transformative year with CAR-T asset acquisition, strong clinical data, and reduced net loss.

Net loss narrowed and R&D spending dropped as strategic alternatives are explored.

Pivotal trial clearance, orphan drug wins, and narrowed Q2 loss highlight strategic progress.

Q1 2025 saw pipeline progress, regulatory wins, and a $10.9M net loss for Tempest.

Amezalpat delivered a six-month OS gain in HCC and is advancing to a pivotal Phase 3 trial.

Advanced amezalpat in HCC with regulatory wins, Roche deal, and strong clinical data.

Amezalpat demonstrated strong efficacy and safety in liver cancer, with a pivotal global trial planned.

Advanced pivotal HCC trial, secured new funding, and strengthened cash position.

Amezalpat showed strong phase 2 survival benefits in liver cancer, with phase 3 FDA-backed plans.

Amezalpat delivered a six-month survival gain in HCC, driving plans for a pivotal Phase 3 trial.

Amezalpat improved median OS by six months in first-line liver cancer, with strong safety and broad benefit.

TPST-1120's phase II success in liver cancer propels a global phase III launch, with key data ahead.